Your browser doesn't support javascript.
loading
Preventing Coronary Obstruction During Transcatheter Aortic Valve Replacement: Results From the Multicenter International BASILICA Registry.
Khan, Jaffar M; Babaliaros, Vasilis C; Greenbaum, Adam B; Spies, Christian; Daniels, David; Depta, Jeremiah P; Oldemeyer, J Bradley; Whisenant, Brian; McCabe, James M; Muhammad, Kamran I; George, Isaac; Mahoney, Paul; Lanz, Jonas; Laham, Roger J; Shah, Pinak B; Chhatriwalla, Adnan; Yazdani, Shahram; Hanzel, George; Pershad, Ashish; Leonardi, Robert A; Khalil, Ramzi; Tang, Gilbert H L; Herrmann, Howard C; Agarwal, Shikhar; Fail, Peter S; Zhang, Ming; Pop, Andrei; Lisko, John; Perdoncin, Emily; Koch, Rachel L; Ben-Dor, Itsik; Satler, Lowell F; Zhang, Cheng; Cohen, Jeffrey E; Lederman, Robert J; Waksman, Ron; Rogers, Toby.
Afiliação
  • Khan JM; Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA; Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.
  • Babaliaros VC; Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia, USA.
  • Greenbaum AB; Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia, USA.
  • Spies C; Burlingame Center, BASH-Sutter Health, San Francisco, California, USA.
  • Daniels D; Burlingame Center, BASH-Sutter Health, San Francisco, California, USA.
  • Depta JP; Sands Constellation Heart Institute, Rochester Regional Health, Rochester, New York, USA.
  • Oldemeyer JB; UC Health Heart and Vascular Clinic, Medical Center of the Rockies, Loveland, Colorado, USA.
  • Whisenant B; Department of Cardiology, Intermountain Medical Center, Salt Lake City, Utah, USA.
  • McCabe JM; Section of Interventional Cardiology, University of Washington, Seattle, Washington, USA.
  • Muhammad KI; Section of Interventional Cardiology, Oklahoma Heart Institute, Tulsa, Oklahoma, USA.
  • George I; Department of Surgery, NewYork-Presbyterian/Columbia University Irving Medical Center, New York, New York, USA.
  • Mahoney P; Structural Heart Center, Sentara Heart Hospital, Norfolk, Virginia, USA.
  • Lanz J; Department of Cardiology, Bern University Hospital, Bern, Switzerland.
  • Laham RJ; Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Shah PB; Department of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Chhatriwalla A; St. Luke's Mid America Heart Institute, St. Luke's Hospital of Kansas City, Kansas City, Missouri, USA.
  • Yazdani S; Section of Structural Heart Disease, Carient Heart and Vascular, Manassas, Virginia, USA.
  • Hanzel G; Department of Cardiology, Beaumont Hospital, Royal Oak, Michigan, USA.
  • Pershad A; Section of Interventional Cardiology, Banner University Medical Center, Phoenix, Arizona, USA.
  • Leonardi RA; Lexington Heart and Vascular Center, Lexington Medical Center, West Columbia, South Carolina, USA.
  • Khalil R; Department of Cardiology, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA.
  • Tang GHL; Department of Cardiovascular Surgery, Mount Sinai Hospital, New York, New York, USA.
  • Herrmann HC; Section of Interventional Cardiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Agarwal S; Geisinger Heart Institute, Geisinger Medical Center, Danville, Pennsylvania, USA.
  • Fail PS; Section of Interventional Cardiology, Cardiovascular Center of the South, Houma, Louisiana, USA.
  • Zhang M; Department of Cardiovascular Services, Swedish Medical Center, Seattle, Washington, USA.
  • Pop A; AMITA Health Medical Group Heart and Vascular, Alexian Brothers Medical Center, Elk Grove Village, Illinois, USA.
  • Lisko J; Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia, USA.
  • Perdoncin E; Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia, USA.
  • Koch RL; Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia, USA.
  • Ben-Dor I; Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.
  • Satler LF; Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.
  • Zhang C; Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.
  • Cohen JE; Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.
  • Lederman RJ; Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Waksman R; Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. Electronic address: ron.waksman@medstar.net.
  • Rogers T; Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA; Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.
JACC Cardiovasc Interv ; 14(9): 941-948, 2021 05 10.
Article em En | MEDLINE | ID: mdl-33958168
ABSTRACT

OBJECTIVES:

This study sought to determine the safety of the BASILICA (bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction) procedure.

BACKGROUND:

Transcatheter aortic valve replacement causes coronary artery obstruction in 0.7% of cases, with 40% to 50% mortality. BASILICA is a procedure to prevent coronary obstruction. Safety and feasibility in a large patient cohort is lacking.

METHODS:

The international BASILICA registry was a retrospective, multicenter, real-world registry of patients at risk of coronary artery obstruction undergoing BASILICA and transcatheter aortic valve replacement. Valve Academic Research Consortium-2 definitions were used to adjudicate events.

RESULTS:

Between June 2017 and December 2020, 214 patients were included from 25 centers in North America and Europe; 72.8% had bioprosthetic aortic valves and 78.5% underwent solo BASILICA. Leaflet traversal was successful in 94.9% and leaflet laceration in 94.4%. Partial or complete coronary artery obstruction was seen in 4.7%. Procedure success, defined as successful BASILICA traversal and laceration without mortality, coronary obstruction, or emergency intervention, was achieved in 86.9%. Thirty-day mortality was 2.8% and stroke was 2.8%, with 0.5% disabling stroke. Thirty-day death and disabling stroke were seen in 3.4%. Valve Academic Research Consortium-2 composite safety was achieved in 82.8%. One-year survival was 83.9%. Outcomes were similar between solo and doppio BASILICA, between native and bioprosthetic valves, and with the use of cerebral embolic protection.

CONCLUSIONS:

BASILICA is safe, with low reported rates of stroke and death. BASILICA is feasible in the real-world setting, with a high procedure success rate and low rates of coronary artery obstruction.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Bioprótese / Próteses Valvulares Cardíacas / Substituição da Valva Aórtica Transcateter Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Bioprótese / Próteses Valvulares Cardíacas / Substituição da Valva Aórtica Transcateter Idioma: En Ano de publicação: 2021 Tipo de documento: Article